1. Alzheimer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement 2019;15:321-87.
3. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015;77:43-51. PMID:
24951455
12. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science 2016;353:777-83. PMID:
27540165
13. Chinta SJ, Woods G, Rane A, Demaria M, Campisi J, Andersen JK. Cellular senescence and the aging brain. Exp Gerontol 2015;68:3-7. PMID:
25281806
14. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68. PMID:
19053174
19. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-40. PMID:
12427740
21. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003;302:885-9. PMID:
14593183
24. Nelson ED, Kavalali ET, Monteggia LM. MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. Curr Biol 2006;16:710-6. PMID:
16581518
25. Patrizi A, Awad PN, Chattopadhyaya B, Li C, Di Cristo G, Fagiolini M. Accelerated hyper-maturation of parvalbumin circuits in the absence of MeCP2. Cereb Cortex 2019 Apr 30;[Epub]. pii: bhz085.
https://doi.org/10.1093/cercor/bhz085.
35. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 1999;286:785-90. PMID:
10531066
37. Le Meur N, Holder-Espinasse M, Jaillard S, Goldenberg A, Joriot S, Amati-Bonneau P, et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. J Med Genet 2010;47:22-9. PMID:
19592390
46. Kumar A, Thakur MK. Epigenetic regulation of presenilin 1 and 2 in the cerebral cortex of mice during development. Dev Neurobiol 2015;75:1165-73. PMID:
25652771
47. Wang C, Wang F, Cao Q, Li Z, Huang L, Chen S. The effect of Mecp2 on heart failure. Cell Physiol Biochem 2018;47:2380-7. PMID:
29991054
48. Sierant M, Kubiak K, Kazmierczak-Baranska J, Warashina M, Kuwabara T, Nawrot B. Evaluation of BACE1 silencing in cellular models. Int J Alzheimers Dis 2009;2009:pii: 257403.
https://doi.org/10.4061/2009/257403.
50. Roux JC, Zala D, Panayotis N, Borges-Correia A, Saudou F, Villard L. Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway. Neurobiol Dis 2012;45:786-95. PMID:
22127389
51. Maphis NM, Jiang S, Binder J, Wright C, Gopalan B, Lamb BT, et al. Whole genome expression analysis in a mouse model of tauopathy identifies MECP2 as a possible regulator of tau pathology. Front Mol Neurosci 2017;10:69
https://doi.org/10.3389/fnmol.2017.00069.eCollection 2017.
53. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 2004;45:583-95. PMID:
15234100
54. LeBlanc AC. The role of apoptotic pathways in Alzheimer’s disease neurodegeneration and cell death. Curr Alzheimer Res 2005;2:389-402. PMID:
16248844
56. Petazzi P, Akizu N, Garcia A, Estaras C, Martinez de Paz A, Rodriguez-Paredes M, et al. An increase in MECP2 dosage impairs neural tube formation. Neurobiol Dis 2014;67:49-56. PMID:
24657916
57. Tsujimura K, Abematsu M, Kohyama J, Namihira M, Nakashima K. Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2. Exp Neurol 2009;219:104-11. PMID:
19427855
63. Roux JC, Dura E, Moncla A, Mancini J, Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 2007;25:1915-22. PMID:
17439480
64. Roux JC, Panayotis N, Dura E, Villard L. Progressive noradrenergic deficits in the locus coeruleus of Mecp2 deficient mice. J Neurosci Res 2010;88:1500-9. PMID:
19998492
65. Panayotis N, Pratte M, Borges-Correia A, Ghata A, Villard L, Roux JC. Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol Dis 2011;41:385-97. PMID:
20951208
66. Palmer A, Qayumi J, Ronnett G. MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively. Mol Cell Neurosci 2008;37:794-807. PMID:
18295506
68. Gil J. Cellular senescence causes ageing. Nat Rev Mol Cell Biol 2019;20:388.
71. Zhang W, Ji W, Yang J, Yang L, Chen W, Zhuang Z. Comparison of global DNA methylation profiles in replicative versus premature senescence. Life Sci 2008;83:475-80. PMID:
18723031
72. Sanders YY, Liu H, Liu G, Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic Biol Med 2015;79:197-205. PMID:
25526894
75. Squillaro T, Hayek G, Farina E, Cipollaro M, Renieri A, Galderisi U. A case report: bone marrow mesenchymal stem cells from a Rett syndrome patient are prone to senescence and show a lower degree of apoptosis. J Cell Biochem 2008;103:1877-85. PMID:
18059018
77. Squillaro T, Alessio N, Cipollaro M, Di Bernardo G, Melone MAB, Peluso G, et al. Senescence phenomena and metabolic alteration in mesenchymal stromal cells from a mouse model of Rett syndrome. Int J Mol Sci 2019;20(10):pii: E2508.
https://doi.org/10.3390/ijms20102508.
78. Squillaro T, Alessio N, Cipollaro M, Renieri A, Giordano A, Galderisi U. Partial silencing of methyl cytosine protein binding 2 (MECP2) in mesenchymal stem cells induces senescence with an increase in damaged DNA. FASEB J 2010;24:1593-603. PMID:
20065105
79. Van Esch H. MECP2 duplication syndrome. Mol Syndromol 2012;2:128-36. PMID:
22679399
80. Zeev BB, Yaron Y, Schanen NC, Wolf H, Brandt N, Ginot N, et al. Rett syndrome: clinical manifestations in males with MECP2 mutations. J Child Neurol 2002;17:20-4. PMID:
11913564